Successful treatment of refractory rash in paraneoplastic amyopathic dermatomyositis.
Skin involvement in dermatomyositis does not always parallel muscle disease and can be the most active or severe component of the disease, failing to respond to therapeutic interventions that are adequate for myositis and other systemic involvement. This case refers to a resistant paraneoplastic amyopathic dermatomyositis rash which readily resolved with intravenous immunoglobulin (IVIG), practically in the form of monotherapy. This observation gains particular significance considering that IVIG is still regarded as a second-line therapeutic regimen in the treatment of dermatomyositis despite its prevalence in matters of safety.
Aslanidis
Spyros
S
B' Propaedeutic Department of Internal Medicine, Hippokration General Hospital, Konstantinoupoleos 49, Thessaloniki 54642, Greece. saslan@med.auth.gr
Pyrpasopoulou
Athina
A
Kartali
Nikoleta
N
Zamboulis
Chryssanthos
C
D000328:Adult; D003882:Dermatomyositis / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D004359:Drug Therapy, Combination; D005076:Exanthema / Q000188:drug therapy / Q000209:etiology / Q000473:pathology*; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008775:Methylprednisolone / Q000627:therapeutic use; D010257:Paraneoplastic Syndromes / Q000473:pathology*; D011239:Prednisolone / Q000627:therapeutic use; D012867:Skin; D016896:Treatment Outcome
D005938:Glucocorticoids; D016756:Immunoglobulins, Intravenous; D006886:Hydroxychloroquine; D011239:Prednisolone; D008775:Methylprednisolone